The poor pharmacokinetics and poor specificity of NT-3, combined with the inability of NT-3 to reach the vast expanse of target receptors (from neuromuscular junctions to motor neuron cell bodies in spinal cord behind the blood brain barrier) makes them unsuitable as systemic drugs, and poor therapeutic agents for ALS. This evidence concerns the gene NTF3 and amyotrophic lateral sclerosis.